[Benign prostatic hyperplasia medical treatment: systematic review of the literature by the CTMH/AFU].

[1]  T. Wilt,et al.  Serenoa repens for benign prostatic hyperplasia. , 2012, The Cochrane database of systematic reviews.

[2]  T. Tammela,et al.  Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. , 2011, European urology.

[3]  A. Descazeaud,et al.  Traitement médical de l'hyperplasie bénigne de prostate , 2009 .

[4]  P. Abrams,et al.  Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. , 2009, European urology.

[5]  J. Imperato-McGinley,et al.  5α‐Reductase Isozymes and Androgen Actions in the Prostate , 2009, Annals of the New York Academy of Sciences.

[6]  E. Belgrano,et al.  Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report. , 2009, The journal of sexual medicine.

[7]  C. Roehrborn,et al.  Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. , 2008, The Journal of urology.

[8]  R. Armstrong,et al.  Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. , 2008, Mayo Clinic proceedings.

[9]  C. Stief,et al.  A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. , 2008, European urology.

[10]  M. Elhilali,et al.  Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3‐year experience in real‐life practice , 2008, BJU international.

[11]  K. McVary,et al.  Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. , 2007, The Journal of urology.

[12]  M. Emberton,et al.  Self-management for men with lower urinary tract symptoms , 2006, BMJ : British Medical Journal.

[13]  C. Roehrborn,et al.  Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. , 2006, JAMA.

[14]  W. Hellstrom,et al.  Effects of acute treatment with tamsulosin versus alfuzosin on ejaculatory function in normal volunteers. , 2006, The Journal of urology.

[15]  D. Tindall,et al.  Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. , 2004, The Journal of urology.

[16]  G. Cunningham,et al.  Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. , 2004, The Journal of clinical endocrinology and metabolism.

[17]  C. Roehrborn,et al.  The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. , 2003, The New England journal of medicine.

[18]  Michael M Lieber,et al.  Journal Review , 2003, International Society of Hair Restoration Surgery.

[19]  P. Boyle,et al.  Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. , 2002, Urology.

[20]  P. Boyle,et al.  [Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study]. , 2002, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

[21]  J H Wasson,et al.  5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs cooperative study. , 1998, The Journal of urology.

[22]  C. Roehrborn,et al.  The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. , 1998, The New England journal of medicine.

[23]  T. Wilt,et al.  Pygeum africanum for benign prostatic hyperplasia. , 1998, The Cochrane database of systematic reviews.

[24]  S. Akimoto,et al.  The natural history of benign prostatic hyperplasia. , 1997, Harvard men's health watch.

[25]  C. Roehrborn,et al.  The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. , 2010, European urology.

[26]  C. Roehrborn,et al.  Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study. , 2005, Urology.

[27]  A. Tubaro.  Urinary retention in patients with BPH treated with finasteride or placebo over 4 years. , 2001 .

[28]  A. Tewari,et al.  Overview of alpha-blocker therapy for benign prostatic hyperplasia. , 1998, Urology.

[29]  T. Wilt,et al.  Tamsulosin for benign prostatic hyperplasia. , 1997, The Medical letter on drugs and therapeutics.

[30]  T. Wilt,et al.  Terazosin for benign prostatic hyperplasia. , 1994, The Medical letter on drugs and therapeutics.